| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
PEGs
PROTAC Linkers; Biotin-binding proteins (avidin/streptavidin). |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a linker molecule, Biotin-PEG4-SH itself has no intrinsic biological activity; it is used to introduce a biotin tag and a thiol handle into PROTAC molecules or other bioconjugates. The biotin group binds with extremely high affinity (Kd ~10-15 M) to avidin and streptavidin, enabling the capture and detection of the conjugated molecule in pull-down assays, Western blotting, ELISA, and other affinity-based techniques. The thiol (SH) group can be used for conjugation via disulfide bond formation (with other thiols) or via thiol-maleimide Michael addition with maleimide-containing molecules to form stable thioether bonds. The PEG4 spacer provides water solubility and flexibility, ensuring that the biotin group is accessible for streptavidin binding. |
| ln Vivo |
No specific in vivo activity has been reported for this linker alone; its activity is derived from the final conjugate after conjugation with appropriate ligands.
|
| Enzyme Assay |
N/A; this compound is not assessed in isolated enzyme/receptor binding assays. As a synthetic intermediate, its quality is typically confirmed by analytical methods such as HPLC and NMR, with a standard purity of ≥95%. The biotin-streptavidin interaction can be confirmed by a colorimetric or fluorescence-based binding assay (e.g., biotin-4-fluorescein displacement assay). The thiol content can be quantified using Ellman's reagent (DTNB). The PEG4 spacer can be characterized by mass spectrometry.
|
| Cell Assay |
N/A; this linker is not tested alone in cell-based assays. It is used as a building block for constructing biotinylated PROTACs. In a typical synthesis, the thiol group is reacted with a maleimide-containing PROTAC component (e.g., a target protein ligand or an E3 ligase ligand functionalized with maleimide) via Michael addition at pH 6.5-7.5. The resulting biotinylated PROTAC is then used in cell-based assays. For example, cells are treated with the biotinylated PROTAC, lysed, and the biotinylated species (including any bound target proteins) are captured on streptavidin-coated beads for Western blotting or mass spectrometry analysis.
|
| Animal Protocol |
N/A; no animal studies are performed with the linker alone. For a complete biotinylated PROTAC, in vivo studies could involve administering the compound to animals, then harvesting tissues, preparing lysates, and performing streptavidin pull-downs to assess target engagement and PROTAC distribution. The biotin tag enables sensitive detection and purification from complex biological matrices.
|
| ADME/Pharmacokinetics |
This compound has a molecular weight of 479.65, a molecular formula of C20H37N3O6S2, and a standard purity of ≥95%. For storage, it should be kept as a powder at -20degC for up to 3 years, protected from light, and stored under nitrogen. In a solvent, it can be stored at -80degC for 6 months or at -20degC for 1 month (protected from light, stored under nitrogen). It is soluble in DMSO (50 mg/mL) and other organic solvents. The product should be stored in a sealed container, protected from light and moisture. The thiol group is sensitive to oxidation and should be handled under an inert atmosphere. CAS: 2762393-22-4.
|
| Toxicity/Toxicokinetics |
This product is for research use only and is not for human or veterinary use. Standard chemical safety precautions should be observed during handling. The thiol group is sensitive to oxidation and should be handled under an inert atmosphere (e.g., nitrogen or argon). The product should be stored away from oxidizing agents. It is not an approved therapeutic drug and has not been cleared for clinical use. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.
|
| References |
[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
|
| Additional Infomation |
The combination of a biotin affinity tag and a thiol conjugation handle on a PEG4 spacer provides a versatile tool for PROTAC research. The thiol group enables site-specific conjugation to maleimide-functionalized ligands, which is a common strategy for attaching ligands to linkers. The biotin tag allows for the detection, capture, and purification of the resulting PROTAC or its protein targets using streptavidin-based assays, facilitating studies of target engagement, ternary complex formation, and cellular distribution. The PEG4 spacer provides a water-soluble, flexible linker that ensures the biotin group is accessible for streptavidin binding and reduces non-specific interactions. This linker is also widely used in surface modification, nanoparticle functionalization, protein labeling, and affinity assays.
|
| Exact Mass |
479.212
|
|---|---|
| CAS # |
2762393-22-4
|
| PubChem CID |
162642635
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
31
|
| Complexity |
517
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)NCCOCCOCCOCCOCCS)NC(=O)N2
|
| InChi Key |
NIJSULOOONHHJS-LNLFQRSKSA-N
|
| InChi Code |
InChI=1S/C20H37N3O6S2/c24-18(4-2-1-3-17-19-16(15-31-17)22-20(25)23-19)21-5-6-26-7-8-27-9-10-28-11-12-29-13-14-30/h16-17,19,30H,1-15H2,(H,21,24)(H2,22,23,25)/t16-,17-,19-/m0/s1
|
| Chemical Name |
5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[2-[2-[2-[2-(2-sulfanylethoxy)ethoxy]ethoxy]ethoxy]ethyl]pentanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
